Key facts
- It has raised $50.5M; the latest was Grant ($11.2M) in May 2025.
- Notable investors include European Union, Gates Foundation, OrbiMed, Coalition for Epidemic Preparedness Innovations, AstraZeneca — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Ethris
- ·The full record, as it builds
Funding rounds
No funding rounds for Ethris are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ethris
Developer of stabilized non-immunogenic mRNA platform designed to develop innovative therapies and vaccines. The company's platform uses a proprietary mRNA-modification technology and lipid nanoparticle formulation to provide versatile, multi-route, multi-cargo delivery options for intramuscular, inhaled, or nasal administration and is suitable for several genetic medicine payloads, enabling healthcare providers to treat monogenic genetic diseases, including asthma and rare respiratory diseases.
- Sector
- Healthcare
- HQ
- Planegg, Germany
- Employees
- 51
- Website
- ethris.com/
- Ownership
- Privately Held (backing)
Ethris doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ethris shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ethris in its N-PORT filings yet. We sweep new filings monthly.